{
    "Trade/Device Name(s)": [
        "Xenta Drug Screen Cup",
        "Xenta Drug Screen Dipcard"
    ],
    "Submitter Information": "Xenta Biomedical Science Co., Ltd.",
    "510(k) Number": "K231137",
    "Predicate Device Reference 510(k) Number(s)": [
        "K122809"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DIS",
        "JXM",
        "DKZ",
        "DJR",
        "DJG",
        "LCM"
    ],
    "Summary Letter Date": "May 19, 2023",
    "Summary Letter Received Date": "April 21, 2023",
    "Submission Date": "April 21, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.3150",
        "21 CFR 862.3170",
        "21 CFR 862.3100",
        "21 CFR 862.3620",
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Barbiturate test system",
        "Benzodiazepine test system",
        "Amphetamine test system",
        "Methadone test system",
        "Opiate test system",
        "Unclassified Enzyme Immunoassay Phencyclidine"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Barbiturates (Secobarbital)",
        "Benzodiazepines (Oxazepam)",
        "Amphetamine (D-Amphetamine)",
        "Methadone",
        "Oxycodone",
        "Phencyclidine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Lateral flow chromatographic immunoassay",
        "Competitive binding immunochromatographic assay"
    ],
    "Methodologies": [
        "Immunochemistry"
    ],
    "Submission Type(s)": [
        "Assay",
        "Cup",
        "Dipcard"
    ],
    "Document Summary": "FDA 510(k) summary for Xenta Drug Screen Cup and Xenta Drug Screen Dipcard for qualitative detection of drugs and drug metabolites in human urine by lateral flow immunoassay.",
    "Indications for Use Summary": "Qualitative detection of drugs and drug metabolites (barbiturates, benzodiazepines, amphetamine, methadone, oxycodone, phencyclidine) in human urine at specified cutoff concentrations; preliminary analytical results for prescription use.",
    "fda_folder": "Toxicology"
}